Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zai Lab Limited (ZLAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures related to its American Depositary Shares listed on the Nasdaq Global Market. Zai Lab is a research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on oncology, immunology, neuroscience, and infectious disease. Its SEC filings offer detailed information on financial performance, risk factors, capital structure, and key corporate agreements.
Through this page, users can review Zai Lab’s current reports on Form 8-K, which have covered topics such as quarterly financial results and the entry into a material definitive agreement for a renminbi-denominated revolving credit facility to support working capital needs in mainland China. These filings also describe how certain information, including earnings press releases furnished as exhibits, is treated for purposes of the Securities Exchange Act of 1934.
In addition to 8-Ks, investors can use this page as a starting point to locate Zai Lab’s annual and other periodic reports filed with the SEC, which discuss its dual-engine strategy, commercial portfolio in China, and global research and development programs. For a biopharmaceutical company like Zai Lab, these documents are important for understanding product revenue sources, R&D investment, licensing arrangements for medicines such as VYVGART, NUZYRA, ZEJULA, AUGTYRO, and COBENFY, and the financial implications of its pipeline.
Stock Titan enhances the raw filing data with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items such as new credit facilities, changes in operations, or significant clinical and commercial milestones referenced in the filings. Real-time updates from EDGAR, combined with organized access to forms including 8-K and other SEC documents, allow users to monitor ZLAB’s regulatory reporting and corporate actions efficiently.
Chen Yajing, Chief Financial Officer of Zai Lab Ltd (ZLAB), reported a sale of 4,096 American Depositary Shares (ADSs) on 08/08/2025. Each ADS represents ten ordinary shares, and the ADSs are fully fungible with ordinary shares. The reported sale price was $34.01 per ADS and the transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2025. Following this disposition the reporting person beneficially owned 16,908 ADSs. The Form 4 discloses no derivative transactions and was signed by an attorney-in-fact on behalf of the reporting person.
Zai Lab director and CEO Du Ying reported exercising and selling American Depositary Shares (ADSs) in matched transactions. On 08/08/2025 and 08/11/2025 she exercised two separate blocks of 50,000 ADS-equivalent stock options each at an exercise price of $0.60 per ADS and contemporaneously sold the same amounts under a pre-existing Rule 10b5-1 trading plan adopted on November 20, 2024. The reported weighted-average sale prices were $34.7431 and $34.6363, with disclosed price ranges for each sale. Each ADS represents 10 ordinary shares. Following the reported transactions the Form 4 shows beneficial ownership of 536,962 ADSs and remaining derivative holdings of 96,387 stock options. The Form notes the options had fully vested as of October 22, 2020 and offers to provide per-price sale details to regulators or security holders.
Zai Lab Limited (ZLAB) filed a Form 144 reporting a proposed sale of 50,000 American Depositary Shares (ADSs) through Fidelity Brokerage on 08/12/2025 for an aggregate market value of $1,712,555.53. The form shows the ADSs were acquired on 08/12/2025 from the issuer upon exercise of an option originally granted on 10/22/2015, with payment in cash. The filing lists 421,725,450 shares outstanding, so the proposed block equals about 0.0119% of outstanding ADSs.
The notice also discloses prior dispositions by the same seller (listed as Ying Du) over the past three months totaling 284,048 ADSs for gross proceeds of $9,022,707.36 (sales dated 05/12/2025–08/11/2025). Sales are reported on NASDAQ and routed through Fidelity Brokerage Services LLC.
Wellington Management and affiliates reported beneficial ownership of 50,084,792 shares of Zai Lab Ltd. common stock, representing 4.51% of the class as of the report. The filing is a Schedule 13G (Amendment No. 5) disclosing that the reporting persons have 0 sole voting or dispositive power, 42,744,773 shares of shared voting power and 50,084,792 shares of shared dispositive power. The securities are owned of record by clients of the Wellington Investment Advisers and the filing states no client is known to own more than 5% of the class. The document lists the issuer's principal executive office in Shanghai and is certified and signed by a Wellington regulatory analyst on 08/12/2025.
Qiming-affiliated investors report beneficial ownership of 66,329,320 ordinary shares of Zai Lab, representing 5.97% of the outstanding class. The disclosed position is held through QM11 Limited and related Cayman entities and is composed, per the filing, of 1,268,000 ADSs and 53,649,320 ordinary shares that together total the reported 66,329,320 shares.
Breakdown in the filing shows Qiming Corporate GP IV, Ltd. and QM11 Limited with sole voting and dispositive power over the 66,329,320 shares, while related Qiming entities report shared voting/dispositive power of 64,299,112 shares (5.79%) and 2,030,208 shares (0.18%). The percentage is calculated using 1,110,783,740 ordinary shares outstanding, as disclosed by the issuer.
Zai Lab Limited (ZLAB) filed a Rule 144 notice disclosing a proposed sale of 50,000 American Depositary Shares through Fidelity Brokerage Services with an aggregate market value of $1,731,814.58. The filing lists the securities as acquired by option granted 10/22/2015 and shows an intended sale date of 08/11/2025. The issuer's outstanding shares are listed as 421,725,450, providing context for the size of the transaction.
The filing also lists prior sales by Ying Du during May–August 2025 totaling 234,048 ADS for aggregate gross proceeds of $7,290,892.36. The filer affirms no undisclosed material adverse information and provides broker details for the planned sale.
Zai Lab Limited has filed a Form 144 disclosing a proposed sale of 50,000 American Depositary Shares (ADS) through Fidelity Brokerage Services LLC on 08/08/2025, with an aggregate market value reported as $1,737,156.02 and 421,725,450 ADS outstanding. The notice states these ADS were acquired under options granted on 10/22/2015 and lists the acquisition and payment date as 08/08/2025 with payment in cash.
The filing also itemizes seven prior ADS sales by Ying Du between 05/09/2025 and 07/02/2025, showing transaction sizes and gross proceeds for each. The form includes the standard Rule 144 representation that the seller is not aware of any undisclosed material adverse information about the issuer.
What: Form 144 notice related to Zai Lab Limited (ZLAB) reporting a proposed sale of American Depositary Shares (ADS).
Key facts:
- Shares to be sold: 3,000 ADS
- Aggregate market value: $105,000.00
- Approximate sale date: 08/08/2025
- Exchange: NASDAQ
- Shares outstanding (issuer): 421,725,450
Acquisition: ADS were acquired on 12/30/2023 via restricted stock vesting from the issuer; consideration/ payment listed as compensation.
Other: The filing states "Nothing to Report" for securities sold in the past three months. Some filer/contact fields in the form content are not populated.
Form 144 filing: An insider of Zai Lab Ltd. (ZLAB), identified as Yajing Chen, notifies intent to sell 4,096 American Depositary Shares (ADS) through Fidelity on or after 08 Aug 2025. The block is valued at roughly US$139,305 based on current market pricing.
The shares were acquired on 25 Jun 2024 via restricted-stock vesting as compensation. Chen has already sold 9,618 ADS (US$288,540) on 02 Jun 2025 and 2,675 ADS (US$96,652) on 26 Jun 2025, bringing recent disposals to 12,293 ADS, or about US$385,192 in proceeds.
Planned and recent sales combined equal 16,389 ADS—just 0.0039% of the 421.7 million shares outstanding—indicating a negligible impact on ownership structure or float. The document contains no operational or financial performance data; it is strictly a regulatory notice of a small insider sale, which may signal mild negative sentiment but is unlikely to move the stock on size alone.
Zai Lab Limited (ZLAB) Q2 2025 10-Q highlights: Net product revenue rose 9 % YoY to $109.1 million, lifting total revenue to $110.0 million. Cost controls drove a 28 % YoY cut in operating loss to $54.9 million and shrank net loss by 49 % to $40.7 million (-$0.04/share). Six-month revenue climbed 15 % to $216.5 million, with net loss down 33 % to $89.2 million.
Growth came from VYVGART (+14 %), NUZYRA (+16 %), XACDURO and AUGTYRO launches, partly offset by a 9 % decline in ZEJULA. R&D expense fell 18 % YoY, SG&A fell 11 %, and operating cash outflow improved to -$92.7 million from -$132.3 million. Cash & equivalents surged to $732.2 million after maturing $330 million of short-term investments; short-term debt increased to $174.5 million (2.66 % avg. rate).
- Q2 gross margin ~61 % (product revenue vs. cost of product revenue).
- Shares outstanding: 1.10 billion; ADS float 421.7 million.
- Pivotal pipeline events: Fast Track for ZL-1310 (SCLC), positive Phase III data for bemarituzumab (FGFR2b gastric), PANOVA-3 success for TTFields, NMPA sNDA acceptance for repotrectinib.
- Subsequent event: doubled CMB revolving facility to RMB500 million (~$69.6 million) on 6 Aug 2025.
Despite stronger top-line momentum and disciplined spending, Zai Lab remains loss-making and dependent on capital markets and credit lines while advancing an expansive late-stage pipeline.